Loading...
XNAS
PRTA
Market cap564mUSD
Apr 08, Last price  
10.48USD
1D
-3.32%
1Q
-25.99%
Jan 2017
-78.69%
IPO
54.12%
Name

Prothena Corporation PLC

Chart & Performance

D1W1MN
P/E
—
P/S
4.17
EPS
—
Div Yield, %
—
Shrs. gr., 5y
6.16%
Rev. gr., 5y
178.00%
Revenues
135m
+47.92%
1,243,000507,0002,658,000676,00050,854,0001,607,0001,055,00027,519,000955,000814,000853,000200,577,00053,905,00091,370,000135,157,000
Net income
-122m
L-16.81%
-12,482,000-29,670,000-41,411,000-40,996,000-7,150,000-80,612,000-160,108,000-153,237,000-155,645,000-77,677,000-111,144,00066,975,000-116,949,000-147,028,000-122,310,000
CFO
-150m
L+12.06%
-9,083,000-19,697,000-42,072,000-32,098,000-683,000-62,455,000-117,269,000-131,183,000-28,276,000-52,969,000-80,362,00092,605,000-108,821,000-133,906,000-150,050,000
Earnings
May 06, 2025

Profile

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
URL
https://www.prothena.com/
IPO date
Dec 21, 2012
Employees
127
Domiciled in
IE
Incorporated in
IE

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
135,157
47.92%
91,370
69.50%
53,905
-73.13%
Cost of revenue
289,718
502,977
192,203
Unusual Expense (Income)
NOPBT
(154,561)
(411,607)
(138,298)
NOPBT Margin
Operating Taxes
(6,620)
(13,452)
(8,656)
Tax Rate
NOPAT
(147,941)
(398,155)
(129,642)
Net income
(122,310)
-16.81%
(147,028)
25.72%
(116,949)
-274.62%
Dividends
Dividend yield
Proceeds from repurchase of equity
(353)
23,583
223,616
BB yield
0.05%
-1.22%
-7.84%
Debt
Debt current
2,610
2,228
6,473
Long-term debt
19,076
22,556
6,473
Deferred revenue
67,405
85,293
Other long-term liabilities
3,448
553
Net debt
(449,702)
(594,046)
(699,672)
Cash flow
Cash from operating activities
(150,050)
(133,906)
(108,821)
CAPEX
(298)
(2,810)
(464)
Cash from investing activities
(298)
(2,773)
(464)
Cash from financing activities
1,554
45,103
241,457
FCF
(145,732)
(406,145)
(123,515)
Balance
Cash
471,388
618,830
710,406
Long term investments
2,212
Excess cash
464,630
614,262
709,923
Stockholders' equity
(1,101,803)
(979,494)
(832,482)
Invested Capital
1,603,020
1,621,213
1,546,843
ROIC
ROCE
EV
Common stock shares outstanding
53,772
53,216
47,369
Price
13.85
-61.89%
36.34
-39.68%
60.25
21.96%
Market cap
744,742
-61.49%
1,933,869
-32.24%
2,853,982
19.21%
EV
295,040
1,339,823
2,154,310
EBITDA
(153,668)
(410,679)
(137,554)
EV/EBITDA
Interest
6,696
Interest/NOPBT